This Small-Cap Biotech Stock Is Tracking A Crucial Bullish Technical Milestone – And Retail Traders Are Taking Notice

• Avalo is looking to sell 19.73 million shares at $17.75 each, a 9% premium over Tuesday’s closing price.
• Avalo plans to use the proceeds, alongside existing cash reserves, to advance development of Abdakibart, its skin inflammation treatment.
• On Tuesday, Avalo said its Phase 2 trial of Abdakibart met its primary endpoint.

Shares of Avalo Therapeutics (AVTX) skyrocketed nearly 45% in pre-market trading on Wednesday, as investors cheered the biotech firm’s latest data from a Phase 2 trial to treat a type of skin inflammation, as well as a capital raise to support its pipeline.

If the pre-market levels hold after the opening bell, AVTX shares would trade at their highest levels in more than two years, while also breaching the key 50-day moving average (50-DMA) for the first time in nearly a month.

Offering Priced At A Premium Over AVTX Stock’s Tuesday Closing Price

Avalo Therapeutics is expected to raise around $375 million via a public offering, selling 19.73 million shares at $17.75 each, along with pre-funded warrants for 1.4 million shares priced at a similar level. This represents a 9% premium over the stock’s closing price on Tuesday.

The company also granted underwriters a 30-day option to purchase up to an additional 3.17 million shares on the same terms. The deal is set to close on May 7, 2026.

Avalo plans to use the proceeds, alongside existing cash reserves, to advance development of Abdakibart, including an upcoming Phase 3 data readout. Remaining funds will support working capital and general corporate needs.

AVTX’s Treatment Meets Primary Endpoint In Phase 2 Study

On Tuesday, Avalo reported strong Phase 2 results from its Lotus trial of Abdakibart, an investigational treatment for patients with moderate-to-severe hidradenitis suppurativa, a chronic inflammatory skin condition.

The study met its primary endpoint, with 75% reductions observed in 42.2% of patients on the 150 mg dose and 42.9% on the 300 mg dose at Week 16, both statistically significant and among the highest reductions reported in similar trials.

Abdakibart was well tolerated, with mostly mild to moderate side effects and no unexpected safety issues. Based on these results, Avalo plans to advance the treatment into Phase 3 development.

Retail Pegs $21 As AVTX’s Support

Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, while message volumes on the counter surged 5,900% over a 24-hour period.

Chatter focused on the offering, with one user saying the stock could fall from its current levels and settle at $21.

Another user also saw $21 as a key level, adding that despite the strong fundamentals, the stock price won’t climb to $30 on Wednesday.

AVTX shares have declined 11% so far this year.

For updates and corrections, email newsroom[at]stocktwits[dot]com.